DOCSLIB.ORG

( 12 ) United States Patent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) United States Patent US010589003B2 (12 ) United States Patent ( 10 ) Patent No.: US 10,589,003 B2 Raad (45 ) Date of Patent : Mar. 17 , 2020 ( 54 ) METHODS FOR COATING SURFACES WITH (58 ) Field of Classification Search ANTIMICROBIAL AGENTS CPC A61L 29/16 See application file for complete search history . (71 ) Applicant: The Board of Regents of the University of Texas System , Austin , ( 56 ) References Cited TX (US ) U.S. PATENT DOCUMENTS (72 ) Inventor: Issam Raad , Missouri City, TX (US ) 3,635,652 A 1/1972 Streck (73 ) Assignee : The Board of Regents of the 4,015,937 A 4/1977 Miyamoto et al . University of Texas System , Austin , 4,107,121 A 8/1978 Stoy TX (US ) (Continued ) ( * ) Notice: Subject to any disclaimer , the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP 0300961 1/1989 U.S.C. 154 (b ) by 0 days . EP 0348947 6/1989 (Continued ) ( 21) Appl. No .: 15 /920,698 ( 22 ) Filed : Mar. 14 , 2018 OTHER PUBLICATIONS (65 ) Prior Publication Data U.S. Appl. No. 08 / 150,472 , Sherertz . (Continued ) US 2018/0303977 A1 Oct. 25 , 2018 Primary Examiner Dah - Wei D. Yuan Related U.S. Application Data Assistant Examiner - Andrew J Bowman (63 ) Continuation of application No. 11/ 560,300 , filed on (74 ) Attorney, Agent, or Firm - Parker Highlander PLLC Nov. 15 , 2006 , now abandoned . (60 ) Provisional application No. 60 / 738,198 , filed on Nov. ( 57 ) ABSTRACT 18 , 2005 . Disclosed are methods for coating or impregnating a surface with an antimicrobial agent that involve contacting the (51 ) Int. Ci. surface with a composition that includes an antimicrobial AGIL 29/16 ( 2006.01 ) agent and a solvent, and curing the surface by applying heat . AOIN 25/24 ( 2006.01 ) Also disclosed are methods for reducing the risk of devel AOIN 25/34 ( 2006.01 ) opment or progression of an infection in a subject in need of A61L 27/54 ( 2006.01 ) a medical device , that involve coating or impregnating a A61L 31/16 ( 2006.01 ) surface of the medical device with an antimicrobial agent (52 ) U.S. CI. and then curing the surface by applying heat, wherein the CPC A61L 29/16 ( 2013.01) ; AOIN 25/24 risk of development or progression of an infection is ( 2013.01 ) ; AOIN 25/34 ( 2013.01) ; A61L 27/54 reduced . ( 2013.01) ; A61L 31/16 ( 2013.01 ) ; AGIL 2300/406 (2013.01 ) ; A61L 2300/442 (2013.01 ) 18 Claims, 18 Drawing Sheets Durability of Spectrum compared to Heated Mino Rifampin catheters over 12 weeks - tested against MRSA 4798 35 30 25 ZoneofInhibition(mm) 20 15 10 5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 Days Silicone Spectrum Silicone - MR1 US 10,589,003 B2 Page 2 ( 56 ) References Cited WO WO 2000/007574 2/2000 WO WO 2000/065915 11/2000 U.S. PATENT DOCUMENTS WO WO 2001/054661 8/2001 WO WO 2002/082907 10/2002 4,233,263 A 11/1980 Schaeffer WO WO 2007/024974 3/2007 4,349,029 A 9/1982 Mott 4,442,133 A 4/1984 Greco et al . OTHER PUBLICATIONS 4,592,920 A 6/1986 Murtfeldt 4,863,445 A 9/1989 Mayhan et al. 4,895,566 A 1/1990 Lee U.S. Appl. No. 10 /044,836 , Raad . 4,917,686 A 4/1990 Bayston “ Biofilm : disinfecting biofilms using hydrogen peroxide/ silver based 4,952,419 A 8/1990 Bayston et al. biocide , ” Accepta : Leading eChemical Procurement, http : // accepta . 5,013,306 A 5/1991 Solomon et al . com , 2004 . 5,236,355 A * 8/1993 Brizzolara A61C 19/063 “ Removal of residual microbicide from sterilised medical devices 433/80 5,308,611 A 5/1994 Thompson using a neutralising sol. comprising, e.g. ascorbic acid or an 5,310,524 A 5/1994 Campbell et al . enzyme, ” Dialog File , Derwent WPI , Thompson Derwent , 2004 . 5,344,652 A 9/1994 Hall, II et al . “ Synercid I.V. — Dosing, ” website found at http ://www.synercid . 5,362,754 A 11/1994 Raad et al . com /dosing /default.htm . , Printed Aug. 11 , 2000 . 5,589,507 A 12/1996 Hall, II " Synercid ( R ) Approved in UK , ” Company News on Call. Article 5,616,119 A 4/1997 Davis found at http://www.prnewswire.com/cgi-bin/stories.pl?ACCT+105 5,624,704 A * 4/1997 Darouiche A61L 27/54 & STORY + /www / sto ... 000099630 . Dated Sep. 5 , 2000 . 427 / 2.24 “ Synercid , a new antibiotic , approved in the European Union ; first 5,688,516 A 11/1997 Raad 5,709,672 A 1/1998 Illner Avenits Pharma product approval, ” Company News on Call. Article 5,756,145 A 5/1998 Darouiche found at http://www.prnewswire.com/cgi-bin/stories.pl?ACCT+105 5,811,471 A 9/1998 Shanbrom & STORY + www / sto ... / 000110315. Printed Sep. 5 , 2000 . 5,820,607 A 10/1998 Tcholakiran et al . “ Synercid , Compassionate Use Antibiotic ,” webstie found at www . 5,820,918 A 10/1998 Ronan et al. cystic-1.org/handbook/html/synercid_compassionate_use_an.htm . 5,840,343 A 11/1998 Hall , II et al. Printed Sep. 5 , 2000 . 5,853,745 A 12/1998 Dariouche 5,871,692 A 2/1999 Haire et al. “ The breakthrough technology behind STERRAD sterilization sys 5,902,283 A 5/1999 Darouiche et al. tems, ” Advanced Sterilization Products , Johnson & Johnson Com 5,928,916 A 7/1999 Keogh pany, http://www.sterrad.com . 6,068,972 A 5/2000 Levy “ US FDA Approval of Synercid ( quinupristin /dalfopristin ) I.V., ” 4th 6,162,487 A 12/2000 Darouiche Scientia Europaea Forum News Report, Sep. 20 , 1999. Found at 6,165,484 A 12/2000 Raad et al . http://www.rhone-poulenc.com/bodyu/nw990052.htm . Printed Sep. 6,187,768 B1 2/2001 Wele et al. 5 , 2000 . 6,193,994 B1 2/2001 Lee et al. 6,261,457 B1 7/2001 Wenthold et al. Aeschlimann , et al ., “ Treatment of vancomycin - resistant Enterococ 6,267,979 B1 7/2001 Raad cus faecium with RP 59500 ( quinupristin -dalfopristin ) administered 6,350,251 B1 2/2002 Prosl et al . by intermittent or continuous infusion , alone or in combination with 6,361,524 B1 3/2002 Odell et al . doxycycline , in an in vitro pharmocodynamic infection model with 6,368,317 B2 4/2002 Chang simulated endocardial vegetations ,” Antimicrob . Agents Chemother. , 6,428,799 B1 8/2002 Cen et al. 42 : 2710-2717 , 1998 . 6,448,006 B1 9/2002 Levy 6,503,539 B2 1/2003 Gestrelius et al. Aumercier, et al. , “ P59500 .: A proposed mechanism for its bacte 6,509,319 B1 1/2003 Raad et al . ricidal activity ,” J. Antimicrob . Chemother ., 30 ( Suppl. A ) : 9-14 , 6,585,934 B1 7/2003 Oberleitner et al . 1992 . 6,592,564 B2 7/2003 Finch Bergeron and Montay , “ The pharmacokinetics of quinupristin / 6,679,870 B1 1/2004 Finch et al . dalfopristin in laboratory animals and in humans, ” J. Antimicrob . 6,685,694 B2 2/2004 Finch et al. Chemoter. , 39( Suppl . A ) : 129-138 , 1997 . 2001/0047195 A1 11/2001 Crossley et al . Bhatnager and Sundaram , “ Studies on antibacterial properties of 2002/0007175 A1 1/2002 Chang gentian violet impregnated silastic , ” Indian J.Med . Res. , [ A ]97 :206 2002/0052404 A1 5/2002 Hunter 208, 1993 . 2002/0087156 A1 7/2002 Maguire et al . Blot, et al. , “ Diagnosis of catheter- related bacteremia : a prospective 2002/0133072 A1 9/2002 Wang comparison of the time to positivity of hub -blood versus peripheral 2003/0007939 A1 1/2003 Murad blood cultures, " Lancet , 354 : 1071-1077 , 1999 . 2003/0032605 A1 2/2003 Raad et al. Chaiban et al. , “ A rapid method of impregnating endotracheal tubes 2003/0065292 Al 4/2003 Darouiche and urinary catheters with gendine : a novel antiseptic agent, ” 2003/0078242 Al 4/2003 Raad et al . Journal of Antimicrobial Chemotherapy 55 :51-56 , 2005. 2004/0254545 Al 12/2004 Rider, II et al . Chatzinikolaou et al. , “ Minocycline and Edta ( M - EDTA ) as a flush 2005/0013836 A1 1/2005 Raad solution for implantable ports ( IP ) used in pediatric cancer patients, " 2005/0197634 Al 9/2005 Raad et al . Shea Merck Healthcare Epidemiology Search Abstracts , 2002 . Curbelo , et al ., “ Treatment and outcome in 100 patients with FOREIGN PATENT DOCUMENTS vancomycin - resistant enterococcal (VRE ) bacteremia ,” Abstract J - 7 . In Program and abstracts of the 37th Interscience Conference on EP 0328421 8/1989 Antimicrobial Agents and Chemotherapy , Washington , DC ., 1997. EP 0865785 9/1998 Desautels et al. , “ Maintenance of sterility in urinary drainage bags ,>>” EP 1044686 10/2000 EP 1245247 10/2002 Surg . Gynecol. Obstet. , 154 ( 6 ) : 838-840 , 1982 . GB 2007096 5/1979 Dever , et al. , “ Treatment of vancomycin - resistant Enterococcus WO WO 1994/010838 5/1994 faecium infections with an investigational streptogramin antibiotic WO WO 1995/005203 2/1995 ( quinupristin /dalfopristin ) : A report of fifteen cases, ” Microb . Drug WO WO 1995/032625 12/1995 Resist. , 2 : 407-413 , 1996 . WO WO 1997/018707 5/1997 Donelli et al, “ Pharmacokinetics of anticancer agents in patients WO WO 1999/017791 4/1999 with impaired liver function ,” Abstract, European Journal of Can WO WO 2000/001238 1/2000 cer, Pergamon Press, UK , 34 ( 1 ) :33-46 , 1998 . US 10,589,003 B2 Page 3 ( 56 ) References Cited Moellering, Jr., “ Vancomycin - resistant Enterococci, " Clinical Infec tious Diseases , 26 : 1196-1199 , 1998 . OTHER PUBLICATIONS Montecalvo , et al. , “ Bloodstream infections with vancomycin resistant Enterococci, ” Arch . Intern . Med . , 156 : 1458-1462, 1996 . Edmond , et al. , “ Vancomycin -resistant enterococcal bacteremia : Moreno , et al ., 1994. “ An old antibiotic for a new multiple -resistant Natural history and attributable mortality ,” Clin .
Load more

Recommended publications
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Caenorhabditis Elegans Assay
    Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay Ikechukwu Okoli1, Jeffrey J. Coleman1, Emmanouil Tempakakis1, W. Frank An2, Edward Holson2, Florence Wagner2, Annie L. Conery3, Jonah Larkins-Ford3, Gang Wu3, Andy Stern2, Frederick M. Ausubel3, Eleftherios Mylonakis1* 1 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, 3 Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Abstract Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of the microscopic nematode Caenorhabditis elegans. The C. elegans–C. albicans infection model was previously adapted to screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228 compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis. Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity of the compound in a single assay.
    [Show full text]
  • Design and in Vitro Characterization of Flutrimazole Microspheres Loaded Topical Emulgel
    Online - 2455-3891 Vol 12, Issue 9, 2019 Print - 0974-2441 Research Article DESIGN AND IN VITRO CHARACTERIZATION OF FLUTRIMAZOLE MICROSPHERES LOADED TOPICAL EMULGEL MUTHADI RADHIKA REDDY1*, SOUMYASTUTIPATNAIK2 Department of School of Pharmacy, Guru Nanak Institutions Technical Campus, Hyderabad, Telangana, India. Email: [email protected] Received: 28 May 2019, Revised and Accepted: 26 July 2019 ABSTRACT Objective: Flutrimazole is a topical antifungal agent which displays potent broad spectrum in vitro activity against dermatophytes, filamentous fungi, and yeasts. The purpose of the present study is to formulate and evaluate microspheres loaded topical gel containing flutrimazole as model drug microspheres were prepared using aqueous ionotropic gelation method. Methods: Different polymers, the different drug to polymer(s) ratio(s) and other parameters were screened to study their effects on the properties of microspheres and to optimize each parameter. The controlled release emulgel was formulated by changing the polymer ratio. Fourier transform infrared study confirmed the purity of the drug, concede no interaction between the drug and excipients and analyze the parameters affecting the morphology and other characteristics of the resultant products employing scanning electron microscopy. Results: Microspheres loaded topical gel has been shown that encapsulation and controlled release of flutrimazole could reduce the side effect while also reducing percutaneous absorption when administered to the skin. The microspheres obtained
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]
  • Efficacy and Safety of Luliconazole (1%) Cream Versus Clotrimazole (1%) Cream in Tinea Infections of Skin
    EFFICACY AND SAFETY OF LULICONAZOLE (1%) CREAM VERSUS CLOTRIMAZOLE (1%) CREAM IN TINEA INFECTIONS OF SKIN A COMPARATIVE STUDY. DISSERTATION SUBMITTED TO THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY IN PARTIAL FULFILLMENT FOR THE AWARD OF THE DEGREE OF DOCTOR OF MEDICINE IN PHARMACOLOGY DEPARTMENT OF PHARMACOLOGY TIRUNELVELI MEDICAL COLLEGE TIRUNELVELI – 11 APRIL 2017 BONAFIDE CERTIFICATE This is to certify that the dissertation entitled “EFFICACY AND SAFETY OF LULICONAZOLE (1%) CREAM VERSUS CLOTRIMAZOLE (1%) CREAM IN TINEA INFECTIONS OF SKIN - A COMPARATIVE STUDY” submitted by DR.LAKSHMI PRABHA M to the Tamilnadu Dr. M.G.R. Medical University, Chennai, in partial fulfillment of the requirement for the award of the Degree of Doctor of Medicine in Pharmacology during the academic period 2014 – 2017 is a bonafide research work carried out by her under direct supervision & guidance. PROFESSOR AND H.O.D. DEAN Department of Pharmacology, Tirunelveli Medical College, Tirunelveli Medical College, Tirunelveli. Tirunelveli. CERTIFICATE This is to certify that the dissertation entitled “EFFICACY AND SAFETY OF LULICONAZOLE (1%) CREAM VERSUS CLOTRIMAZOLE (1%) CREAM IN TINEA INFECTIONS OF SKIN - A COMPARATIVE STUDY” submitted by DR.LAKSHMI PRABHA M is an original work done by her in the Department of Pharmacology, Tirunelveli Medical College, Tirunelveli for the award of the Degree of Doctor of Medicine in Pharmacology during the academic period of 2014-2017. Place : Tirunelveli GUIDE Date : Department of Pharmacology Tirunelveli Medical College Tirunelveli. DECLARATION I solemnly declare that the dissertation titled “EFFICACY AND SAFETY OF LULICONAZOLE (1%) CREAM VERSUS CLOTRIMAZOLE (1%) CREAM IN TINEA INFECTIONS OF SKIN-A COMPARATIVE STUDY” is done by me in the Department of Pharmacology, Tirunelveli Medical College, Tirunelveli.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Development of an in Vitro Diagnostic Technique for Malassezia
    Development of an In Vitro Diagnostic Technique for Malassezia furfur A thesis submitted in partial fulfilment of the requirement for the Degree of Master of Science in Microbiology in the University of Canterbury by Stephanie Fiona ~uick University of Canterbury vw+ of Contents 1 ! :) TABLE OF CONTENTS Ta hie of Contents ............................................................ 8 •••••••• 0 ••• "." ••••••••••• 1 List of Tables ............................. o ••••••• o ••••••••••••••••••••••••••••• 0 •••••••••• 0 •••••••••••••• 7 List of Figures ........................................................................................... 8 Abstract............................. o ••••• 0 ••• 0' ••••••••••••••••••••••••••••••••••••••••••••••••••••• 00 •••••• 9 Acknowledgemen ts ..... o ••••• e •••••••••••• e •••••••••••••••••••••••••••••••••••••••• o ••••• o ••••••• e •• l 0 1. INTRODUCTION .o, •• o •••••••• e •••• O' •••• O •••••••••••••••••••••••••••••••••••••••••••••••••••••• 11 1.1 THE GENUS MALASSEZIA ..................................................................... 11 1.2 TAXONOMY OF MALASSEZIA FURFUR .................................................. 12 1.3 MORPHOLOGy .................................................................................... 15 1.4 PATHOGENICITY ................................................................................. 18 1.5 fIABITAT ............................................................................................ 20 1.6 GROWTH OF MALASSEZIA FURFUR IN VITRO ........................................
    [Show full text]